메뉴 건너뛰기




Volumn 17, Issue 3, 2011, Pages 399-406

Low incidence of factor VIII inhibitors in previously untreated patients during prophylaxis, on-demand treatment and surgical procedures, with Octanate®: Interim report from an ongoing prospective clinical study

Author keywords

Factor VIII; Haemophilia A; Inhibitors; Octanate ; Previously untreated patients; Surgery

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; OCTANATE; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

EID: 79955147317     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2010.02428.x     Document Type: Article
Times cited : (23)

References (36)
  • 1
    • 0032722639 scopus 로고    scopus 로고
    • The hemophilias: progress and problems
    • Mannucci PM, Tuddenham EG. The hemophilias: progress and problems. Semin Hematol 1999; 36: 104-17.
    • (1999) Semin Hematol , vol.36 , pp. 104-117
    • Mannucci, P.M.1    Tuddenham, E.G.2
  • 2
    • 79955135530 scopus 로고    scopus 로고
    • Guide for the assessment of clotting factor concentrates. Available from: Regulatory-Guide-2008.pdf.Last updated
    • Farrugia A. Guide for the assessment of clotting factor concentrates. Available from: Regulatory-Guide-2008.pdf.Last updated: 2008.
    • (2008)
    • Farrugia, A.1
  • 3
    • 0033220609 scopus 로고    scopus 로고
    • Treatment of patients with inhibitors: cost issues
    • Goudemand J. Treatment of patients with inhibitors: cost issues. Haemophilia 1999; 5: 397-401.
    • (1999) Haemophilia , vol.5 , pp. 397-401
    • Goudemand, J.1
  • 4
    • 4644334185 scopus 로고    scopus 로고
    • Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction
    • Leissinger CA. Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction. Am J Hematol 2004; 77: 187-93.
    • (2004) Am J Hematol , vol.77 , pp. 187-193
    • Leissinger, C.A.1
  • 5
    • 33751014075 scopus 로고    scopus 로고
    • Genetic risk factors for inhibitors to factors VIII and IX
    • Oldenburg J, Pavlova A. Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia 2006; 12(Suppl 6): 15-22.
    • (2006) Haemophilia , vol.12 , Issue.SUPPL. 6 , pp. 15-22
    • Oldenburg, J.1    Pavlova, A.2
  • 6
    • 0016853978 scopus 로고
    • Proceedings: a more uniform measurement of factor VIII inhibitors
    • Kasper CK, Aledort L, Aronson D et al. Proceedings: a more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 612.
    • (1975) Thromb Diath Haemorrh , vol.34 , pp. 612
    • Kasper, C.K.1    Aledort, L.2    Aronson, D.3
  • 7
    • 11044235586 scopus 로고    scopus 로고
    • Inhibitors in haemophilia: clinical aspects
    • Di Michele D, Rivard G, Hay C et al. Inhibitors in haemophilia: clinical aspects. Haemophilia 2004; 10(Suppl 4): 140-5.
    • (2004) Haemophilia , vol.10 , Issue.SUPPL. 4 , pp. 140-145
    • Di Michele, D.1    Rivard, G.2    Hay, C.3
  • 8
    • 0141482007 scopus 로고    scopus 로고
    • Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group
    • Gringeri A, Mantovani L.G, Scalone L et al. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2009; 102: 2358-63.
    • (2009) Blood , vol.102 , pp. 2358-2363
    • Gringeri, A.1    Mantovani, L.G.2    Scalone, L.3
  • 9
    • 84949470041 scopus 로고    scopus 로고
    • Immune tolerance: high-dose regimen
    • Rodrigues-Merchan EC, Lee CA eds., 1st edn. Oxford: Blackwell Science
    • Brackmann HH, Wallny T. Immune tolerance: high-dose regimen. In: Rodrigues-Merchan EC, Lee CA eds. Inhibitors in Patients with Haemophilia, 1st edn. Oxford: Blackwell Science, 2002: 45-8.
    • (2002) Inhibitors in Patients with Haemophilia , pp. 45-48
    • Brackmann, H.H.1    Wallny, T.2
  • 10
    • 37749001670 scopus 로고    scopus 로고
    • von Willebrand factor in high-purity factor VIII complex concentrates: chaperone protein or key to therapies? A meeting report
    • Federici AB, Mannucci PM, Marco P. von Willebrand factor in high-purity factor VIII complex concentrates: chaperone protein or key to therapies? A meeting report. Haemophilia 2008; 14: 133-9.
    • (2008) Haemophilia , vol.14 , pp. 133-139
    • Federici, A.B.1    Mannucci, P.M.2    Marco, P.3
  • 11
    • 0034284456 scopus 로고    scopus 로고
    • Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper
    • Colowick AB, Bohn RL, Avorn J et al. Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper. Blood 2000; 96: 1698-702.
    • (2000) Blood , vol.96 , pp. 1698-1702
    • Colowick, A.B.1    Bohn, R.L.2    Avorn, J.3
  • 12
    • 33750974213 scopus 로고    scopus 로고
    • Immune tolerance: critical issues of factor dose, purity and treatment complications
    • DiMichele DM. Immune tolerance: critical issues of factor dose, purity and treatment complications. Haemophilia 2006; 12(Suppl 6): 81-5.
    • (2006) Haemophilia , vol.12 , Issue.SUPPL. 6 , pp. 81-85
    • DiMichele, D.M.1
  • 13
    • 41749124711 scopus 로고    scopus 로고
    • Immune tolerance and choice of concentrates
    • Rodrigues-Merchan EC, Lee CA eds., 1st edn. Oxford: Blackwell Science Ltd
    • Kreuz W. Immune tolerance and choice of concentrates. In: Rodrigues-Merchan EC, Lee CA eds. Inhibitors in Patients with Haemophilia, 1st edn. Oxford: Blackwell Science Ltd, 2002: 55-8.
    • (2002) Inhibitors in Patients with Haemophilia , pp. 55-58
    • Kreuz, W.1
  • 14
    • 79955135734 scopus 로고    scopus 로고
    • European Medicines Agency. Assessing the efficacy and safety of human plasma derived factor VIII:C and factor IX:C products in clinical trials in haemophiliacs before and after authorisation. Report No.: CPMP/BPWP/198/95.
    • European Medicines Agency. Assessing the efficacy and safety of human plasma derived factor VIII:C and factor IX:C products in clinical trials in haemophiliacs before and after authorisation. 2009. Report No.: CPMP/BPWP/198/95.
    • (2009)
  • 15
    • 0028837315 scopus 로고
    • The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability
    • Verbruggen B, Novakova I, Wessels H et al. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-51.
    • (1995) Thromb Haemost , vol.73 , pp. 247-251
    • Verbruggen, B.1    Novakova, I.2    Wessels, H.3
  • 16
    • 0025847974 scopus 로고
    • The design and analysis of half-life and recovery studies for factor VIII and factor IX. Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis
    • Morfini M, Lee M, Messori A. The design and analysis of half-life and recovery studies for factor VIII and factor IX. Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis. Thromb Haemost 1991; 66: 384-6.
    • (1991) Thromb Haemost , vol.66 , pp. 384-386
    • Morfini, M.1    Lee, M.2    Messori, A.3
  • 17
    • 0036249147 scopus 로고    scopus 로고
    • Inhibitor development in correlation to factor VIII genotypes
    • Oldenburg J, El-Maarri O, Schwaab R. Inhibitor development in correlation to factor VIII genotypes. Haemophilia 2002; 8(Suppl 2): 23-9.
    • (2002) Haemophilia , vol.8 , Issue.SUPPL. 2 , pp. 23-29
    • Oldenburg, J.1    El-Maarri, O.2    Schwaab, R.3
  • 18
    • 0029617930 scopus 로고
    • Haemophilia A: mutation type determines risk of inhibitor formation
    • Schwaab R, Brackmann HH, Meyer C et al. Haemophilia A: mutation type determines risk of inhibitor formation. Thromb Haemost 1995; 74: 1402-6.
    • (1995) Thromb Haemost , vol.74 , pp. 1402-1406
    • Schwaab, R.1    Brackmann, H.H.2    Meyer, C.3
  • 19
    • 0037314020 scopus 로고    scopus 로고
    • Characterization of factor VIII antibody epitopes from haemophilia A patients using cellulose bound FVIII peptide libraries
    • Albert T, Lange S, Oldenburg J et al. Characterization of factor VIII antibody epitopes from haemophilia A patients using cellulose bound FVIII peptide libraries. Hamostaseologie 2003; 23: 13-7.
    • (2003) Hamostaseologie , vol.23 , pp. 13-17
    • Albert, T.1    Lange, S.2    Oldenburg, J.3
  • 20
    • 33646140127 scopus 로고    scopus 로고
    • Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia
    • Astermark J. Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia. Haemophilia 2006; 12(Suppl 3): 52-60.
    • (2006) Haemophilia , vol.12 , Issue.SUPPL. 3 , pp. 52-60
    • Astermark, J.1
  • 21
    • 79955165131 scopus 로고    scopus 로고
    • European Medicines Agency. Guideline on the investigation of human plasma-derived factor VIII and IX products. London; Report No.: CPMP/BPWG/198/95 rev.2.
    • European Medicines Agency. Guideline on the investigation of human plasma-derived factor VIII and IX products. London; 2007. Report No.: CPMP/BPWG/198/95 rev.2.
    • (2007)
  • 22
    • 30344434999 scopus 로고    scopus 로고
    • Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A
    • Goudemand J, Rothschild C, Demiguel V et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2006; 107: 46-51.
    • (2006) Blood , vol.107 , pp. 46-51
    • Goudemand, J.1    Rothschild, C.2    Demiguel, V.3
  • 23
    • 33645963964 scopus 로고    scopus 로고
    • Effect of factor VIII concentrate on leucocyte cytokine receptor expression in vitro: relevance to inhibitor formation and tolerance induction
    • Hodge G, Saxon B, Revesz T. Effect of factor VIII concentrate on leucocyte cytokine receptor expression in vitro: relevance to inhibitor formation and tolerance induction. Haemophilia 2006; 12: 133-9.
    • (2006) Haemophilia , vol.12 , pp. 133-139
    • Hodge, G.1    Saxon, B.2    Revesz, T.3
  • 24
    • 0034917040 scopus 로고    scopus 로고
    • von Willebrand factor in factor VIII concentrates protects against neutralization by factor VIII antibodies of haemophilia A patients
    • Kallas A, Talpsep T. von Willebrand factor in factor VIII concentrates protects against neutralization by factor VIII antibodies of haemophilia A patients. Haemophilia 2008; 7: 375-80.
    • (2008) Haemophilia , vol.7 , pp. 375-380
    • Kallas, A.1    Talpsep, T.2
  • 25
    • 0038383605 scopus 로고    scopus 로고
    • The epidemiology of inhibitors in haemophilia A: a systematic review
    • Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9: 418-35.
    • (2003) Haemophilia , vol.9 , pp. 418-435
    • Wight, J.1    Paisley, S.2
  • 26
    • 0034964673 scopus 로고    scopus 로고
    • Clinical evaluation of B-domain deleted recombinant factor VIII in previously untreated patients
    • Courter SG, Bedrosian CL. Clinical evaluation of B-domain deleted recombinant factor VIII in previously untreated patients. Semin Hematol 2001; 38: 52-9.
    • (2001) Semin Hematol , vol.38 , pp. 52-59
    • Courter, S.G.1    Bedrosian, C.L.2
  • 27
    • 33751010515 scopus 로고    scopus 로고
    • Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development
    • Ettingshausen CE, Kreuz W. Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development. Haemophilia 2006; 12(Suppl 6): 102-6.
    • (2006) Haemophilia , vol.12 , Issue.SUPPL. 6 , pp. 102-106
    • Ettingshausen, C.E.1    Kreuz, W.2
  • 28
    • 33846922841 scopus 로고    scopus 로고
    • Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A
    • Chalmers EA, Brown SA, Keeling D et al. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A. Haemophilia 2007; 13: 149-55.
    • (2007) Haemophilia , vol.13 , pp. 149-155
    • Chalmers, E.A.1    Brown, S.A.2    Keeling, D.3
  • 29
    • 34249690732 scopus 로고    scopus 로고
    • Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study
    • Gouw SC, van der Bom JG, van der Berg HM. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007; 109: 4648-54.
    • (2007) Blood , vol.109 , pp. 4648-4654
    • Gouw, S.C.1    van der Bom, J.G.2    van der Berg, H.M.3
  • 30
    • 33750983966 scopus 로고    scopus 로고
    • Basic aspects of inhibitors to factors VIII and IX and the influence of non-genetic risk factors
    • Astermark J. Basic aspects of inhibitors to factors VIII and IX and the influence of non-genetic risk factors. Haemophilia 2006; 12(Suppl 6): 8-13.
    • (2006) Haemophilia , vol.12 , Issue.SUPPL. 6 , pp. 8-13
    • Astermark, J.1
  • 31
    • 0034994489 scopus 로고    scopus 로고
    • Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age
    • Lorenzo JI, Lopez A, Altisent C et al. Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age. Br J Haematol 2001; 113: 600-3.
    • (2001) Br J Haematol , vol.113 , pp. 600-603
    • Lorenzo, J.I.1    Lopez, A.2    Altisent, C.3
  • 32
    • 24944440876 scopus 로고    scopus 로고
    • Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study
    • Santagostino E, Mancuso ME, Rocino A et al. Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol 2005; 130: 422-7.
    • (2005) Br J Haematol , vol.130 , pp. 422-427
    • Santagostino, E.1    Mancuso, M.E.2    Rocino, A.3
  • 33
    • 0029865410 scopus 로고    scopus 로고
    • Characterization of the factor VIII defect in 147 patients with sporadic hemophilia A: family studies indicate a mutation type-dependent sex ratio of mutation frequencies
    • Becker J, Schwaab R, Moller-Taube A et al. Characterization of the factor VIII defect in 147 patients with sporadic hemophilia A: family studies indicate a mutation type-dependent sex ratio of mutation frequencies. Am J Hum Genet 1996; 58: 657-70.
    • (1996) Am J Hum Genet , vol.58 , pp. 657-670
    • Becker, J.1    Schwaab, R.2    Moller-Taube, A.3
  • 34
    • 2542560221 scopus 로고    scopus 로고
    • The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients
    • Auerswald G, Spranger T, Brackmann HH. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients. Haematologica 2003; 88: EREP05.
    • (2003) Haematologica , vol.88
    • Auerswald, G.1    Spranger, T.2    Brackmann, H.H.3
  • 35
    • 34249711370 scopus 로고    scopus 로고
    • Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study
    • Gouw SC, van der Bom JG, Auerswald G et al. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 2007; 109: 4693-7.
    • (2007) Blood , vol.109 , pp. 4693-4697
    • Gouw, S.C.1    van der Bom, J.G.2    Auerswald, G.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.